Galera Therapeutics to Participate in Fireside Chat at 2020 BTIG Virtual Biotechnology Conference

Rhea-AI Summary

Galera Therapeutics, a clinical-stage biopharmaceutical company (Nasdaq: GRTX), announced that CEO Mel Sorensen will participate in a fireside chat at the 2020 BTIG Virtual Biotechnology Conference on August 10, 2020, at 9:30 a.m. EDT. A live webcast will be available on the company’s Investors page, and an archived version will be posted for 30 days post-event. Galera focuses on developing therapeutics to transform cancer radiotherapy, with lead candidate avasopasem manganese aimed at reducing radiation-induced severe oral mucositis in head and neck cancer patients.

MALVERN, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 2020 BTIG Virtual Biotechnology Conference on Monday, August 10, 2020, at 9:30 a.m. EDT.

A live webcast of the event will be accessible from the Investors page of Galera’s website, investors.galeratx.com. An archived version of the webcast will be available in the News & Events section of the Investors page of Galera’s website for 30 days following the event.

About Galera Therapeutics

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Galera’s lead product candidate is avasopasem manganese (GC4419), a highly selective small molecule superoxide dismutase (SOD) mimetic initially being developed for the reduction of radiation-induced severe oral mucositis (SOM). Avasopasem is being studied in the Phase 3 ROMAN trial for its ability to reduce the incidence and severity of SOM induced by radiotherapy in patients with locally advanced head and neck cancer, its lead indication. It is also being studied in a Phase 2a trial for its ability to reduce the incidence of esophagitis induced by radiotherapy in patients with lung cancer and in a pilot Phase 1/2 trial in combination with stereotactic body radiation therapy (SBRT) in patients with locally advanced pancreatic cancer. The FDA granted Fast Track and Breakthrough Therapy designations to avasopasem for the reduction of SOM induced by radiotherapy. Galera is developing a second product candidate, GC4711, for SBRT which successfully completed Phase 1 trials in healthy volunteers. Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com.

Investor Contacts:
Christopher Degnan
Galera Therapeutics, Inc.
610-725-1500
cdegnan@galeratx.com 

Jennifer Porcelli
Solebury Trout
646-378-2962
jporcelli@soleburytrout.com 

Media Contact:
Gina Cestari
6 Degrees
917-797-7904
gcestari@6degreespr.com 

FAQ

When will GRTX CEO Mel Sorensen speak at the BTIG Virtual Biotechnology Conference?

Mel Sorensen will participate in the analyst-led fireside chat on August 10, 2020, at 9:30 a.m. EDT.

Where can I watch the GRTX conference webcast?

The live webcast can be accessed from the Investors page on Galera Therapeutics' website.

What is Galera Therapeutics known for?

Galera Therapeutics specializes in developing novel therapeutics to improve cancer radiotherapy, with a focus on avasopasem manganese.

What is avasopasem manganese used for?

Avasopasem manganese is designed to reduce severe oral mucositis caused by radiation therapy in head and neck cancer patients.

What type of trials is GRTX currently conducting?

Galera is conducting Phase 3 trials for avasopasem in severe oral mucositis and has additional studies for esophagitis and pancreatic cancer.